Beyond anaemia management: evolving role of erythropoietin therapy in neurological disorders, multiple myeloma and tumour hypoxia models - PubMed (original) (raw)
Review
doi: 10.1159/000088285. Epub 2005 Oct 21.
Affiliations
- PMID: 16244507
- DOI: 10.1159/000088285
Review
Beyond anaemia management: evolving role of erythropoietin therapy in neurological disorders, multiple myeloma and tumour hypoxia models
Marc Boogaerts et al. Oncology. 2005.
Abstract
Recombinant human erythropoietin (epoetin) has become the standard of care in the treatment of anaemia resulting from cancer and its treatment, and chronic kidney disease. The discovery that erythropoietin and its receptor are located in regions outside the erythropoietic system has led to interest in the potential role of epoetin in other tissues, such as the central nervous system. Animal studies have shown that systemically applied epoetin can cross the blood-brain barrier, where it reduces tissue injury associated with stroke, blunt trauma and experimental autoimmune encephalomyelitis. Pilot studies in humans have shown that epoetin treatment given within 8 h of stroke reduces infarct size and results in a significantly better outcome when compared with placebo treatment. Studies also suggest that epoetin has the potential to improve cognitive impairment associated with adjuvant chemotherapy in patients with cancer. Anaemia is a major factor causing tumour hypoxia, a condition that can promote changes within neoplastic cells that further tumour survival and malignant progression and also reduces the effectiveness of several anticancer therapies including radiotherapy and oxygen-dependent cytotoxic agents. Use of epoetin to prevent or correct anaemia has the potential to reduce tumour hypoxia and improve treatment outcome. Several therapeutic studies in anaemic animals with experimental tumours have shown a beneficial effect of epoetin on delaying tumour growth. Furthermore, clinical observations in patients with multiple myeloma and animal studies have suggested that epoetin has an antimyeloma effect, mediated via the immune system through activation of CD8+ T cells. Therefore, the role of epoetin may go well beyond that of increasing haemoglobin levels in anaemic patients, although additional studies are required to confirm these promising results.
Copyright 2005 S. Karger AG, Basel.
Similar articles
- Can erythropoietin therapy improve survival?
Glaspy J, Dunst J. Glaspy J, et al. Oncology. 2004;67 Suppl 1:5-11. doi: 10.1159/000080705. Oncology. 2004. PMID: 15486447 Review. - rHuEPO and treatment outcomes: the preclinical experience.
Ludwig H. Ludwig H. Oncologist. 2004;9 Suppl 5:48-54. doi: 10.1634/theoncologist.9-90005-48. Oncologist. 2004. PMID: 15591422 - Evolving treatment strategies for anaemia in cancer: experience with epoetin beta.
Aapro M, San Miguel J. Aapro M, et al. Oncology. 2004;67 Suppl 1:17-22. doi: 10.1159/000080704. Oncology. 2004. PMID: 15486449 Review. - rHuEPO and improved treatment outcomes: potential modes of action.
Blackwell K, Gascón P, Sigounas G, Jolliffe L. Blackwell K, et al. Oncologist. 2004;9 Suppl 5:41-7. doi: 10.1634/theoncologist.9-90005-41. Oncologist. 2004. PMID: 15591421 Review. - Epoetin beta therapy in patients with solid tumours.
Pronzato P, Jassem J, Mayordomo J. Pronzato P, et al. Crit Rev Oncol Hematol. 2006 Apr;58(1):46-52. doi: 10.1016/j.critrevonc.2005.08.010. Epub 2005 Oct 5. Crit Rev Oncol Hematol. 2006. PMID: 16169242 Review.
Cited by
- Prognostic Nomogram for Patients with Radical Surgery for Non-Metastatic Colorectal Cancer Incorporating Hematological Biomarkers and Clinical Characteristics.
Long P, Zang Y, Wang H, Liang X, Xie X, Han Z, Lin D, Wang Z, Huang S, Chen C. Long P, et al. Onco Targets Ther. 2020 Mar 9;13:2093-2102. doi: 10.2147/OTT.S240843. eCollection 2020. Onco Targets Ther. 2020. PMID: 32210575 Free PMC article. - Preoperative mean corpuscular hemoglobin affecting long-term outcomes of hepatectomized patients with hepatocellular carcinoma.
Huang P, Liu C, Li B, Zheng Y, Zou R, Huang J, Hu Z, Yuan Y. Huang P, et al. Mol Clin Oncol. 2016 Feb;4(2):229-236. doi: 10.3892/mco.2015.705. Epub 2015 Dec 10. Mol Clin Oncol. 2016. PMID: 26893867 Free PMC article. - Protein phosphatase 2A catalytic subunit α (PP2Acα) maintains survival of committed erythroid cells in fetal liver erythropoiesis through the STAT5 pathway.
Chen W, Gu P, Jiang X, Ruan HB, Li C, Gao X. Chen W, et al. Am J Pathol. 2011 May;178(5):2333-43. doi: 10.1016/j.ajpath.2011.01.041. Am J Pathol. 2011. PMID: 21514445 Free PMC article. - Hypoxia and radiation therapy: past history, ongoing research, and future promise.
Rockwell S, Dobrucki IT, Kim EY, Marrison ST, Vu VT. Rockwell S, et al. Curr Mol Med. 2009 May;9(4):442-58. doi: 10.2174/156652409788167087. Curr Mol Med. 2009. PMID: 19519402 Free PMC article. - Breast tumour angiogenesis.
Fox SB, Generali DG, Harris AL. Fox SB, et al. Breast Cancer Res. 2007;9(6):216. doi: 10.1186/bcr1796. Breast Cancer Res. 2007. PMID: 18190723 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials